News stories about Mallinckrodt PLC (NYSE:MNK) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mallinckrodt PLC earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 93 out of 100, meaning that recent media coverage is extremely likely to have an impact on the company’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Analysts Update Their Price Target On Mallinckrodt Plc (NYSE:MNK) (healthcaremenu.net)
- Mallinckrodt PLC (MNK) Bonds Trading 1.9% Lower (techzolix.com)
- Mallinckrodt Plc breached its 50 day moving average in a Bearish Manner : MNK-US : July 7, 2017 (finance.yahoo.com)
- Technical Snapshots for These Generic Drugs Stocks — Mallinckrodt, Patheon, Zoetis, and Innocoll (bizjournals.com)
- Mallinckrodt PLC to Post FY2017 Earnings of $7.40 Per Share, Cantor Fitzgerald Forecasts (MNK) (americanbankingnews.com)
A number of brokerages have recently commented on MNK. Cantor Fitzgerald began coverage on shares of Mallinckrodt PLC in a research note on Friday, June 16th. They set an “overweight” rating and a $52.00 price objective on the stock. Wells Fargo & Company reissued an “outperform” rating and issued a $83.50 price target on shares of Mallinckrodt PLC in a research note on Wednesday, June 21st. Jefferies Group LLC cut shares of Mallinckrodt PLC to a “buy” rating and dropped their price target for the company from $95.00 to $70.00 in a research note on Monday, March 13th. BMO Capital Markets dropped their price target on shares of Mallinckrodt PLC from $79.00 to $69.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 10th. Finally, BidaskClub raised shares of Mallinckrodt PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. One analyst has rated the stock with a sell rating, six have given a hold rating and fifteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $74.31.
Mallinckrodt PLC (MNK) traded down 1.71% during midday trading on Monday, hitting $41.91. The stock had a trading volume of 549,559 shares. The firm’s market cap is $4.16 billion. The stock has a 50-day moving average price of $42.92 and a 200 day moving average price of $47.15. Mallinckrodt PLC has a one year low of $38.80 and a one year high of $85.83.
Mallinckrodt PLC (NYSE:MNK) last announced its earnings results on Monday, May 8th. The company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.05. The firm had revenue of $810.90 million for the quarter, compared to the consensus estimate of $781.23 million. Mallinckrodt PLC had a return on equity of 16.33% and a net margin of 16.01%. The firm’s revenue for the quarter was down .6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.01 EPS. On average, analysts predict that Mallinckrodt PLC will post $7.55 earnings per share for the current year.
In other Mallinckrodt PLC news, VP Steven J. Romano purchased 1,000 shares of the stock in a transaction dated Friday, June 9th. The shares were acquired at an average price of $39.88 per share, for a total transaction of $39,880.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Coleman N. Lannum III purchased 1,968 shares of the stock in a transaction dated Friday, May 12th. The shares were acquired at an average price of $46.20 per share, for a total transaction of $90,921.60. The disclosure for this purchase can be found here. Insiders have acquired a total of 5,818 shares of company stock worth $248,608 in the last ninety days. 0.77% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.wkrb13.com/markets/2285703/somewhat-positive-news-coverage-extremely-likely-to-affect-mallinckrodt-plc-mnk-stock-price.html.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285703/somewhat-positive-news-coverage-extremely-likely-to-affect-mallinckrodt-plc-mnk-stock-price.html
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.